Federico Simonetta Selected Research

Federico Simonetta Research Topics

Disease

20	Neoplasms (Cancer) 05/2024 - 11/2015
10	Graft vs Host Disease (Graft-Versus-Host Disease) 02/2024 - 01/2016
5	Hematologic Neoplasms (Hematological Malignancy) 01/2024 - 01/2017
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2023 - 01/2021
5	Infections 01/2023 - 11/2015
3	Hematologic Diseases (Blood Diseases) 12/2023 - 01/2022
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 05/2015
2	Disease Progression 01/2023 - 01/2019
2	Colorectal Neoplasms (Colorectal Cancer) 05/2022 - 03/2006
2	Bone Marrow Failure Disorders 01/2022 - 01/2016
2	Inflammation (Inflammations) 01/2019 - 01/2016
2	Brain Diseases (Brain Disorder) 01/2016 - 01/2013
2	HIV Infections (HIV Infection) 10/2014 - 05/2012
1	cell-associated neurotoxicity 05/2024
1	Melanoma (Melanoma, Malignant) 05/2024
1	Hodgkin Disease (Hodgkin's Disease) 01/2024
1	Residual Neoplasm 12/2023
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2023
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2023
1	Pathologic Complete Response 01/2023
1	Neuroinflammatory Diseases 01/2023
1	Leukemia 01/2023
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 11/2022
1	Lymphoma (Lymphomas) 05/2022
1	Oncogene Addiction 01/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2022
1	Experimental Melanoma 06/2020
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2019
1	Psychomotor Agitation (Akathisia) 01/2018
1	Lupus Nephritis 01/2017
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2015
1	Atrial Fibrillation 01/2013
1	Abscess 01/2013
1	Sarcoma (Soft Tissue Sarcoma) 04/2012
1	Neuroblastoma 04/2012
1	Carcinoma (Carcinomatosis) 03/2006

Drug/Important Bio-Agent (IBA)

5	Chimeric Antigen ReceptorsIBA 05/2024 - 06/2020
3	Transcription Factors (Transcription Factor)IBA 01/2023 - 10/2014
2	AntigensIBA 12/2023 - 06/2020
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2019
2	Rituximab (Mabthera)FDA Link 01/2017 - 07/2015
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2024
1	pembrolizumabIBA 01/2024
1	Brentuximab VedotinIBA 01/2024
1	Interleukin-3 (Interleukin 3)IBA 12/2023
1	Immunoconjugates (Immunoconjugate)IBA 12/2023
1	Monoclonal AntibodiesIBA 12/2023
1	CCAAT-Enhancer-Binding ProteinsIBA 01/2023
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2023
1	fms-Like Tyrosine Kinase 3IBA 01/2023
1	LipidsIBA 01/2023
1	Sorafenib (BAY 43-9006)FDA Link 01/2023
1	Triggering Receptor Expressed on Myeloid Cells-1IBA 01/2023
1	defibrotideIBA 11/2022
1	Firefly LuciferasesIBA 05/2022
1	Granzymes (Granzyme)IBA 05/2022
1	trametinibIBA 01/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	venetoclaxIBA 11/2021
1	AMP-Activated Protein KinasesIBA 11/2021
1	Surface Antigens (Surface Antigen)IBA 06/2020
1	Thymidine KinaseIBA 06/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Nucleic AcidsIBA 01/2019
1	Inosine Triphosphate (ITP)IBA 01/2019
1	LigandsIBA 01/2019
1	Tumor Biomarkers (Tumor Markers)IBA 01/2019
1	LuciferasesIBA 01/2019
1	belimumabIBA 01/2017
1	Imipenem Drug Combination Cilastatin (Primaxin)FDA Link 01/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016
1	Prostaglandins FIBA 01/2016
1	Fas Ligand Protein (Fas Ligand)IBA 01/2016
1	InterferonsIBA 01/2016
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2013
1	Metronidazole (Metric)FDA LinkGeneric 01/2013
1	Cyclin-Dependent Kinase Inhibitor p16IBA 04/2012
1	alpha-MSHIBA 04/2012
1	Type 1 Melanocortin ReceptorIBA 04/2012
1	Cyclin-Dependent Kinase 4IBA 04/2012
1	Irinotecan (Camptosar)FDA LinkGeneric 03/2006
1	Topoisomerase I InhibitorsIBA 03/2006

Therapy/Procedure

12	Hematopoietic Stem Cell Transplantation 02/2024 - 05/2015
10	Therapeutics 05/2024 - 10/2014
8	Immunotherapy 05/2024 - 01/2020
5	Cell Transplantation 01/2023 - 01/2017
4	Transplantation 01/2024 - 01/2020
2	Stem Cell Transplantation 01/2021 - 01/2018
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 12/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 06/2020
1	Highly Active Antiretroviral Therapy (HAART) 05/2012
1	Aftercare (After-Treatment) 03/2006